Crescent Biopharma (CBIO) Corporate Presentation summary

Mission and strategic focus

• Aims to deliver transformative therapies for cancer patients, focusing on solid tumors.

• Pipeline includes potentially best-in-class therapies targeting significant unmet needs in oncology.

Pipeline and scientific innovation

• Lead program CR-001 is a cooperative, tetravalent PD-1 x VEGF bispecific antibody designed to replicate ivonescimab's clinical success.

• CR-001 shows cooperative binding, enhancing anti-tumor activity and safety, with preclinical data mirroring ivonescimab.

• CR-002 and CR-003 are topoisomerase inhibitor ADCs with undisclosed targets, offering broad potential across solid tumors.

• All programs are engineered for best-in-class efficacy, safety, and developability, with combination strategies to maximize impact.

Market opportunity and competitive landscape

• PD-(L)1 therapies represent a $50B+ market, with Keytruda as the leading drug.

• Ivonescimab, a cooperative PD-1 x VEGF bispecific, has shown superior efficacy to pembrolizumab in NSCLC, setting a new standard.

• CR-001 is positioned to follow or surpass ivonescimab in multiple indications, leveraging similar mechanism and design.

• ADCs with topoisomerase payloads have demonstrated superior efficacy and safety over microtubule-based ADCs.